文献速递胃肠外科围术期管理与 ERAS

阿维莫泮促进CRS-HIPEC术后胃肠功能恢复的随机对照试验

Alvimopan for Enhanced Gastrointestinal Recovery after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Randomized Controlled Trial.
PubMed 文献 · J Am Coll Surg · 2022-10-17

这项双盲随机安慰剂对照单中心试验纳入62例接受肿瘤细胞减灭术联合腹腔热灌注化疗(CRS-HIPEC)的患者,评估围术期阿维莫泮对术后肠功能恢复的作用。结果显示阿维莫泮组GI-2达标时间(117小时 vs 152小时,p=0.04)和首次排便时间(67小时 vs 89小时,p=0.02)均显著短于安慰剂组,不良事件发生率无显著差异。

要点

  • 阿维莫泮可缩短CRS-HIPEC术后GI-2达标时间。
  • 阿维莫泮可加速首次排便恢复。
  • 不良事件发生率与安慰剂组无显著差异。

核心结论

  • 围术期阿维莫泮耐受性良好,可加速CRS-HIPEC患者的肠功能恢复。

研究设计与样本

  • 双盲、随机、安慰剂对照、单中心、经IRB批准的试验,2018年3月至2020年4月纳入接受CRS-HIPEC的患者。
  • 共62例符合标准并纳入分析,安慰剂组n=32,阿维莫泮组n=30。
  • 患者术前及术后每日两次接受阿维莫泮或安慰剂,持续7天。

主要发现

  • 主要终点GI-2(耐受固体食物且首次排便的时间)中位值:安慰剂组152小时(95%CI 134, 204),阿维莫泮组117小时(95%CI 102, 158),p=0.04。
  • 首次排便时间中位值:安慰剂组89小时(95%CI 71, 114),阿维莫泮组67小时(95%CI 62, 89),p=0.02。
  • 不良事件发生率、延长性肠梗阻患者比例及其他次要终点均无显著差异。

临床怎么用

  • 对于接受CRS-HIPEC的患者,可考虑围术期使用阿维莫泮以加速术后肠功能恢复。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Surgical management of peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is associated with prolonged length of stay and time to return of bowel function. Alvimopan is a peripherally acting opioid antagonist that reduces postoperative ileus. We sought to determine the efficacy of alvimopan on return of bowel function in patients undergoing CRS-HIPEC. METHODS: A double-blind, randomized, placebo-controlled, single-institution, IRB-approved trial was conducted in patients undergoing CRS-HIPEC from March 2018 to April 2020. Patients received alvimopan or placebo preoperatively and twice daily postoperatively for 7 days. The primary endpoint (GI-2) was the time of tolerance of solid food and first bowel movement (BM). Secondary endpoints were the proportion of patients with prolonged ileus, time to first flatus, first BM, tolerance of solid food, discharge, and adverse events (AEs). RESULTS: Sixty-two patients met eligibility criteria and received placebo (n = 32) or alvimopan (n = 30), and were included in the analysis. The median time to GI-2 was 152 hours (95% CI 134, 204) in the placebo arm versus 117 hours (95% CI 102, 158) in the alvimopan arm (p = 0.04). The time to BM was 89 hours (95% CI 71, 114) in the placebo arm vs 67 hours (95% CI 62, 89) in the alvimopan arm (p = 0.02). There were no significant differences in AE rates, proportion of patients with prolonged ileus, or other secondary endpoints. CONCLUSION: Perioperative alvimopan was well tolerated and accelerated bowel function recovery in patients undergoing CRS-HIPEC.

来源:J Am Coll Surg,查看原文。版权归原作者所有。

引用

  1. Baumgartner JM, Chen R, Messer K, et al. Alvimopan for Enhanced Gastrointestinal Recovery after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Randomized Controlled Trial. J Am Coll Surg. 2022. PMID: 36102565. doi:10.1097/XCS.0000000000000305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。